CDP Equity Invests €1 Billion for Significant Share in Angelini Pharma

CDP Equity, the investment arm of the Italian state lender Cassa Depositi e Prestiti, has finalized a major acquisition, injecting €1 billion into Angelini Pharma. This significant financial move grants CDP Equity a 23.5% stake in the pharmaceutical enterprise, positioning it as a substantial minority shareholder, Investing.com reports. The transaction, structured through a dedicated investment vehicle, saw CDP Equity acquire its interest from Angelini Holding. The newly formed entity, named Angelini Pharma 2020 S.p.A., will oversee the pharmaceutical operations. This deal values Angelini Pharma at an estimated €4.25 billion, inclusive of net financial debt. Angelini Pharma, renowned for its focus on brain health, consumer health, and rare diseases, is an integral component of the broader Angelini Industries. The company's strategic priorities include accelerating its international growth, particularly in the United States, and enhancing its capabilities in research and development. The investment from CDP Equity is expected to provide crucial support for these ambitious plans. The collaboration will also target expanding Angelini Pharma's industrial footprint and strengthening its presence in key European markets. The financial backing is anticipated to enable the company to pursue new opportunities for innovation and market penetration, ensuring its competitive edge in the global pharmaceutical landscape. CDP Equity's involvement underscores its commitment to supporting leading Italian companies with strong international growth potential. This partnership is designed to foster sustainable development and expand the reach of Italian excellence in the highly competitive pharmaceutical sector.